TY - JOUR
T1 - Germline mutations in Japanese familial pancreatic cancer patients
AU - Takai, Erina
AU - Yachida, Shinichi
AU - Shimizu, Kyoko
AU - Furuse, Junji
AU - Kubo, Emi
AU - Ohmoto, Akihiro
AU - Suzuki, Masami
AU - Hruban, Ralph H.
AU - Okusaka, Takuji
AU - Morizane, Chigusa
AU - Furukawa, Toru
PY - 2016
Y1 - 2016
N2 - Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDAC).We reviewed 1,197 patients with a pathologically proven PDAC and found that 88 (7.3%) were FPC patients who had at least one first-degree relative with PDAC. There were no significant differences between the FPC cases and sporadic cases in terms of gender, age, tumor location, stage, family history of any cancer except PDAC, and personal history of smoking, other cancers, diabetes mellitus and chronic pancreatitis. In the FPC patients, we then investigated the prevalence of germline mutations in 21 genes associated with hereditary predispositions for pancreatic, breast and ovarian cancers by means of the next-generation sequencing using a custom multiple-gene panel. We found that eight (14.5%) of the 54 FPC patients with available germline DNA carried deleterious mutations in BRCA2, PALB2, ATM, or MLH1. These results indicate that a significant fraction of patients with PDAC in Japan have a family history of pancreatic cancer, and some of them harbor deleterious causative mutations in known FPC predisposition genes.
AB - Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDAC).We reviewed 1,197 patients with a pathologically proven PDAC and found that 88 (7.3%) were FPC patients who had at least one first-degree relative with PDAC. There were no significant differences between the FPC cases and sporadic cases in terms of gender, age, tumor location, stage, family history of any cancer except PDAC, and personal history of smoking, other cancers, diabetes mellitus and chronic pancreatitis. In the FPC patients, we then investigated the prevalence of germline mutations in 21 genes associated with hereditary predispositions for pancreatic, breast and ovarian cancers by means of the next-generation sequencing using a custom multiple-gene panel. We found that eight (14.5%) of the 54 FPC patients with available germline DNA carried deleterious mutations in BRCA2, PALB2, ATM, or MLH1. These results indicate that a significant fraction of patients with PDAC in Japan have a family history of pancreatic cancer, and some of them harbor deleterious causative mutations in known FPC predisposition genes.
KW - ATM
KW - BRCA2
KW - Familial predisposition
KW - PALB2
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84995752640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995752640&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.12490
DO - 10.18632/oncotarget.12490
M3 - Article
C2 - 27732944
AN - SCOPUS:84995752640
SN - 1949-2553
VL - 7
SP - 74227
EP - 74235
JO - Oncotarget
JF - Oncotarget
IS - 45
ER -